The therapeutic monoclonal antibody market

mAbs

Volumn 7, Issue 1, 2015, Pages 9-14

  Ecker, Dawn M ^a   Jones, Susan Dana ^a   Levine, Howard L ^a  

^a BioProcess Technology Consultants Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

DRUG APPROVAL; DRUG MANUFACTURE; DRUG MARKETING; HUMAN; PROCESS DESIGN; PRODUCT DEVELOPMENT; REVIEW; ECONOMICS; EUROPE; MARKETING; UNITED STATES;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; EUROPE; HUMANS; MARKETING; UNITED STATES;

EID: 84921352030     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2015.989042     Document Type: Review

References (20)

1. Bioprocess Technology Consultants [Internet]. Woburn (MA): Bioprocess Technology Consultants, Inc. bioTRAK® database; 2014 [cited 2014 September 14]; [about 2 screens]. Available from: http://www.bptc.com/pipeline-databases.php
2. Pharmaceutical Research and Manufacturers of America. Medicines in development: Biologics 2013 Report [Internet]. Washington, DC: Pharmaceutical Research and Manufacturers of America; 2013 Mar [cited 2014 September 14]. 87 p. Available from: http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf
3. Drugs@FDA [Internet]. Silver Spring (MD): U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 1939- [cited 2014 September 14]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
4. European public assessment reports, human medicines [Internet]. London: The European Medicines Agency. 1995 [cited 2014 September 14]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar-search.jsp&mid=WC0b01ac058001d124
5. Ecker DM, Ransohoff TC, Jones SD, Levine HL. The state of mammalian cell culture biomanufacturing. Woburn (MA): BioProcess Technology Consultants, Inc; 2011 Dec 12; 150 p. Available from: http://www.bptc.com/ECommerce/Reports.
6. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87(3):272-7; PMID:20130567
7. Pavlou AK, Reichert JM. Recombinant protein therapeutics- success rates, market trends and values to 2010. Nat Biotechnol 2004; 22(12):1513-9; PMID:15583654
8. Greb E, Drakulich A. Platform technologies. Pharmaceutical Technol 2012; 36(3):46-52.
9. Rameez S, Mostafa SS, Miller C, Shukla AA. Highthroughput miniaturized bioreactors for cell culture process development: reproducibility, scalability, and control. Biotechnol Prog 2014; 30(3):718-27; PMID:24449637
10. Bhambure R, Kumar K, Rathore AS. High throughput process development for biopharmaceutical drug substances. Trends in Biotech 2011; 29(3):127-35; PMID:21255855
11. Chollangi S, et al. Accelerating purification process development of an early phase MAb with high-throughput automation. Part 1. Bioprocess Int 2014; 12(3):48-52.
12. Chollangi S, et al. Accelerating purification process development of an early phase MAb with high-throughput automation. Part 2. Bioprocess Int 2014; 12(4):32-41.
13. BCC Research. Biologic therapeutic drugs: technologies and global markets. Wellesley (MA): BCC Research, LLC; 2013 Jan. 142 p. Available from: http://www.bccresearch.com/market-research/biotechnology/biologic-therapeutic-drugs-markets-bio079b.html
14. Bilello JA. The agony and ecstasy of "OMIC" technologies in drug development. Curr Mol Med 2005; 5 (1):39-52; PMID:15720269
15. United Nations Development Programme. Human development report 2013: The rise of the South: Human progress in a diverse world [Internet]. NY (NY): United Nations Development Programme; c2013 [cited 2014 September 14]. 216 p. Available from: http://hdr.undp.org/sites/default/files/reports/14/hdr2013-en-complete.pdf
16. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22(11):1393-8; PMID:15529164
17. Lu F, Toh PC, Burnett I, Li F, Hudson T, Amanullah A, Li J. Automated dynamic fed-batch process and media optimization for high productivity cell culture process development. Biotechnol Bioeng 2013; 110 (1):191-205; PMID:22767053
18. Yang WC, Lu J, Kwiatkowski C, Yuan H, Kshirsagar R, Ryll T, Huang YM. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality. Biotechnol Prog 2014; 30(3):616-25; PMID:24574326
19. Povey JF, O'Malley CJ, Root T, Martin EB, Montague GA, Feary M, Trim C, Lang DA, Alldread R, Racher AJ, Smales CM. Rapid high-throughput characterization, classification and selection of recombinant mammalian cell line phenotypes using intact cell MALDI-ToF mass spectrometry fingerprinting and PLS-DA modelling. J Biotechnol 2014; 20(184):84-93.
20. Liu B Spearman M, Doering J, Lattová E, Perreault H, Butler M. The availability of glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site occupancy and the N-glycosylation profile of a monoclonal antibody. J Biotechnol 2014; 170:17-27; PMID:24286971